{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 56,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "other",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a scientific mechanism of action diagram at the bottom.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/42",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.96,
        "x": 0.02,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Mechanism of action flow showing elimination of T-regs, entry of T-lymphocytes, and elimination of tumor vascularization.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31521af4-162e-4b7a-975b-c1ed820d0006",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.48,
        "y": 0.0017
      },
      "kind": "list",
      "text": "Combination Trial Design: iMX-110 + tislelizumab; 30 patient Phase 1b study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57dd285a-b555-40ba-b616-33c0723d8181",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.22,
        "y": 0.0017
      },
      "kind": "list",
      "text": "Study Goal: Demonstrate potential for TSTx in combination therapies; Rapid IMX-110 expansion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d59e7db1-2fee-4b34-9695-ebc7fd5df0c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.75,
        "y": 0.0017
      },
      "kind": "paragraph",
      "text": "Joint Alliance Committee: A Joint Alliance Committee consisting of members from ImmixBio & BeiGene will coordinate the clinical trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c132b52-27a7-4152-9b8d-6ce95e057142",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "paragraph",
      "text": "Scientific Basis: IMX-110 turns “cold” tumors “hot” in genetic (KPC) mouse models of pancreatic cancer. IMX-110 + murine anti-PD-1 survival exceeded by exactly 50% a 4-drug combination.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99a9732d-3694-4dd1-90aa-af5350a4d51a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "As of June 2021, in China, tislelizumab has already been approved or granted conditional approved in 5 cancer indications...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8d89969-3147-49b4-a8ba-69abb812ae49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Trial and Supply Agreement with BeiGene for Tislelizumab (Anti-PD-1 mAb)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8696e4f-8aeb-4992-af12-82772dadd147",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "70d83c4b-1c68-425b-8780-23299562904b",
      "evidence": "title/headline: Clinical Trial and Supply Agreement with BeiGene for Tislelizumab (Anti-PD-1 mAb)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}